1. メタボリックシンドローム診断基準検討委員会. 2005. メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94: 188-203.
2. Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill M., Bouret S, Varma V, Hastings KL, Schug TT, Emeigh Hart SG, Burleson FG. 2018. Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. Toxicol Sci 162: 36-42.
3. GBD 2015 Obesity Collaborators. 2017. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377: 13–27.
4. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, Gundlapalli AV, Boehmer TK, Blanck HM. 2021. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. Morbidity and Mortality Weekly Report 70; 10
5. Fock KM, Khoo JJ. 2013. Diet and exercise in management of obesity and overweight. Gastroenterol Hepatol 28 Suppl 4: 59–63.
6. Fukuda T, Obara K, Saito J, Umeda S, Ano Y. 2020. Effects of Hop Bitter Acids, Bitter Components in Beer, on Cognition in Healthy Adults: A Randomized Controlled Trial. J Agric Food Chem 68: 206-212.
7. Miyata S, Inoue J, Shimizu M, Sato R. 2015. Xanthohumol Improves Diet-induced Obesity and Fatty Liver by Suppressing Sterol Regulatory Element-binding Protein (SREBP) Activation. J Biol Chem 290: 20565–20579.
8. Jan FS, Alan WT, Jeff EC, Max LD. 1999. Fate of xanthohumol and related prenylflavonoids from hops to beer. J. Agric. Food Chem 47: 2421–2428.
9. Herlemann DPR, Labrenz M, Jürgens K, Bertilsson S, Waniek JJ, Andersson AF. 2011. Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea. The ISME journal 5: 1571-1579.
10. Yamashita M, Fukizawa S, Nonaka Y. 2020. Hop-derived prenylflavonoid isoxanthohumol suppresses insulin resistance by changing the intestinal microbiota and suppressing chronic inflammation in high fat diet-fed mice. Eur Rev Med Pharmacol Sci 24: 1537-1547.
11. Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444: 860-867.
12. Suganami T, Ogawa Y. 2010. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leuko Biol 88: 33-39.
13. Kadowaki S, Tamura Y, Someya Y, Takeno K, Kaga H, Sugimoto D, Kakehi S, Funayama T, Furukawa Y, Suzuki R, Nishitani-Yokoyama M, Shimada K, Daida H, Aoki S, Kanazawa A, Kawamori R, Watada H. 2019. Fatty Liver Has Stronger Association With Insulin Resistance Than Visceral Fat Accumulation in Nonobese Japanese Men. Journal of the Endocrine Society 3: 1409–1416.
14. Ozato N, Saito S, Yamaguchi T, Katashima M, Tokuda I, Sawada K, Katsuragi Y, Kakuta M, Imoto S, Ihara K, Nakaji S. 2019. Blautia genus associated with visceral fat accumulation in adults 20-76 years of age.NPJ Biofilms Microbiomes 5: 28.
15. Most J, Penders J, Lucchesi M, Goossens GH, Blaak EE. 2017. Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women. Eur J Clin Nutr 71: 1040–1045.
16. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. 2007. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104: 979–984.
17. Soga T, Ueno Y, Naraoka H, Ohashi Y, Tomita M, Nishioka T. 2002. Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem 74: 2233-2239.
18. Kakiyama G, Muto A, Takei H, Nittono H, Murai T, Kurosawa T, Hofmann AF, Pandak WM, Bajaj JS. 2014. A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J Lipid Res 55: 978-990.
19. Ohashi Y, Hirayama A, Ishikawa T, Nakamura S, Shimizu K, Ueno Y, Tomita M, Soga T. 2008. Depiction of metabolome changes in histidine-starved Escherichia coli by CE- TOFMS. Mol Biosyst 4: 135-147.
20. Ooga T, Sato H, Nagashima A, Sasaki K, Tomita M, Soga T, Ohashi Y. 2011. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol Biosyst 7: 1217-1223.
21. Minato K, Suzuki M, Nagao H, Suzuki R, Ochiai H. 2015. Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1002: 399-410.
22. Russell DW. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137-174.
23. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. 2016. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7: 22-39.
24. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. 2014. Bile acids and the gut microbiome. Curr Opin Gastroenterol 30: 332-338.
25. Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47: 241-259.
26. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499: 97- 101.
27. Kuno T, Hirayama-Kurogi M, Ito S, Ohtsuki S. 2018. Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Sci Rep 8:1253.
28. Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, Soto M, Konishi M, Softic S, Altindis E, Li N, Gerber G, Bry L, Kahn CR. 2016. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest 126: 4430-4443.
29. Dai ZL, Wu G, Zhu WY. 2011. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. Front Biosci (Landmark Ed) 16: 1768-1786.
30. Oliphant K, Allen-Vercoe E. 2019. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 7: 91.
31. Matsumoto M, Kibe R, Ooga T, Aiba Y, Kurihara S, Sawaki E, Koga Y, Benno Y. 2012. Impact of intestinal microbiota on intestinal luminal metabolome. Sci Rep 2: 233.
32. Dewulf EM, Cani PD, Neyrinck AM, Possemiers S, Holle AV, Muccioli GG, Deldicque L, Bindels LB, Pachikian BD, Sohet FM, Mignolet E, Francaux M, Larondelle Y, Delzenne NM. 2011. Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22: 712-722.
33. Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y, Takase K. 2015. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol 15: 100.
34. Most J, Penders J, Lucchesi M, Goossens GH, Blaak EE. 2017. Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women. Eur J Clin Nutr 71: 1040–1045.
35. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.
36. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. 2019. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 25: 1096–1103.
37. Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C, Franzosa EA, Hübenthal M, Rahnavard A, Frost F, Lloyd-Price J, Schirmer M, Lusis AJ, Vulpe CD, Lerch MM, Homuth G, Kacprowski T, Schmidt CO, Nöthlings U., Karlsen TH, Lieb W, Laudes M, Franke A, Huttenhower C. Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition. Cell Host & Microbe 26: 252–264.
38. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al- Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5: e9085.
39. Saito K, Tanaka T, Obata H, Nakamura J, Fukui N, Tonozuka N. 2015. Body fat reducing effect and safety evaluation of long-term consumption of tea containing quercetin glucosides in obese subjects. Jpn Pharmacol Ther 43: 181–194.
40. Tateishi N, Egawa K, Kanzaki N, Kitagawa Y, Shibata H, Kiso Y, Enomoto S, Fukuda D, Nagai R, Sata M. 2009. Effects of quercetin glucosides on diet-induced obesity in mice. Jpn Pharmacol Ther 37: 123–131.
41. Murase T, Nagasawa A, Suzuki J, Hase T, Tokimitsu I. 2002. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 26: 1459–1464.
42. Panche AN, Diwan AD, Chandra SR. 2016. Flavonoids: an overview. Journal of Nutritional Science 5: e47.
43. US Department of Agriculture. USDA database for the flavonoid content of selected foods.
44. Tanaka, T, Kouno I. 2003. Oxidation of Tea Catechins: Chemical Structures and Reaction Mechanism. Food Sci. Technol. Res 9: 128-133
45. IDF Diabetes Atlas 9th Edition
46. Hirakawa Y, Hata J, Yoshinari M, Higashioka M, Yoshida D, Shibata M, Honda T, Sakata S, Kato H, Teramoto T, Maki H, Nishimoto S, Kitazono T, Ninomiya T. 2020. 30-minute postload plasma glucose levels during an oral glucose tolerance test predict the risk of future type 2 diabetes: the Hisayama Study. BMJ Open Diabetes Res Care 8: e001156.
47. 清原 裕. 2018. 糖尿病合併症の時代的変遷と今日の課題:久山町研究. 日本糖尿病 教👉・看護学会誌 22: 50-56.